Associated Papers
Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report.
Wilgucki M et al.
Jto Clinical and Research Reports, 2022
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients.
Yang Z et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2018
Select a paper to view details